See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Meeting with FDA ‘Successful’ Regarding PT-112 in mCRPC

Summary by cancernetwork.com
Following a positive meeting with the FDA, PT-112 is set to advance to a phase 3 trial for patients with metastatic castration-resistant prostate cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

cancernetwork.comcancernetwork.com

Meeting with FDA ‘Successful’ Regarding PT-112 in mCRPC

Following a positive meeting with the FDA, PT-112 is set to advance to a phase 3 trial for patients with metastatic castration-resistant prostate cancer.

Read Full Article
urologytimes.comurologytimes.com

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

The phase 3 study design will now be submitted for final review by the agency.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

urologytimes.com broke the news in on Tuesday, May 20, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

Washington DC icon

Washington DC

News
For You
SearchBlindspotLocal